Clinical Pharmacokinetics of Fluvastatin
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (4) , 263-281
- https://doi.org/10.2165/00003088-200140040-00003
Abstract
Fluvastatin, the first fully synthetic HMG-CoA reductase inhibitor, has been shown to reduce cholesterol in patients with hyperlipidaemia, to prevent subsequent coronary events in patients with...Keywords
This publication has 75 references indexed in Scilit:
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase InhibitorsClinical Pharmacokinetics, 1996
- FluvastatinDrugs, 1996
- HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Binding of Fluvastatin to Blood Cells and Plasma ProteinsJournal of Pharmaceutical Sciences, 1993
- Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Regulation of the mevalonate pathwayNature, 1990